More than two years after its Renflexis (infliximab-abda) biosimilar was awarded a national contract from the US Department of Veterans Affairs, Samsung Bioepis has presented first real-world data, insisting the results demonstrate that patients “can remain stable after switching to another biosimilar, without major safety concerns.”

An advanced immunotherapy for recurrent glioblastoma and the first biosimilar version of Lucentis for age-related macular degeneration have also been submitted for review by the European Medicines Agency for potential pan-EU authorization.

Curon thinks tenalisib can offer a differentiated and safe new therapy for hematologic cancers such as multiple forms of lymphoma. Axis and PharmaEssentia team up on TCR therapy R&D in Taiwan.

Samsung Bioepis has beaten its rivals to become the first firm to announce successful filing of a ranibizumab biosimilar rival to Lucentis in the EU.